Imsidolimab Heads to FDA Review for Generalized Pustular Psoriasis: What to Know

Imsidolimab, a new IL-36 receptor blocker made by Vanda Pharmaceuticals, is under FDA review for the treatment of generalized pustular psoriasis (GPP), with a decision expected by December 12, 2026. In Phase 3 trials, a single IV dose cleared skin in 53% of patients at 4 weeks, compared to 13% on placebo. If approved, it would be only the second FDA-approved drug for this rare and deadly form of psoriasis.

Most people with psoriasis have plaque psoriasis. This type causes the raised, scaly patches many people know. A rarer and more dangerous form called generalized pustular psoriasis (GPP) affects far fewer people. GPP flares can require hospital care and, in severe cases, can be fatal.

For years, people with GPP had almost no FDA-approved treatment options. That’s finally starting to change.

What Is Generalized Pustular Psoriasis?

Generalized pustular psoriasis (GPP) is a rare, severe form of psoriasis that causes sudden flares of painful, pus-filled blisters (pustules) across large areas of the body. Plaque psoriasis develops slowly. GPP flares can strike within hours, bringing fever, chills, rapid heart rate, and extreme fatigue. GPP can threaten life and often requires a hospital stay.

GPP is distinct from plaque psoriasis in several important ways:

• Appearance: Instead of thick, scaly plaques, GPP produces widespread sheets of small, white pustules on red, inflamed skin
• Onset: Flares can develop rapidly, sometimes within hours
• Severity: GPP flares can cause systemic symptoms including fever, dehydration, and organ stress
• Prevalence: GPP is much rarer than plaque psoriasis, affecting a small fraction of the psoriasis population
• Genetics: Many cases of GPP are linked to mutations in the IL36RN gene, which makes the IL-36 inflammatory pathway abnormally active

A person can have GPP alone, or they can have both GPP and plaque psoriasis. Both conditions stem from immune system problems, but different pathways drive them. That’s why treatments that work for plaque psoriasis don’t always control GPP.

How Does Imsidolimab Work?

Imsidolimab is an antibody drug that blocks the IL-36 receptor. In many GPP patients, changes in the IL36RN gene make the IL-36 pathway too active. Imsidolimab blocks the receptor where IL-36 attaches. This directly targets the immune process that drives GPP flares. This makes it a precision treatment matched to the biology of the disease.

The IL-36 pathway matters for GPP because of a genetic link. The IL36RN gene normally produces a protein that keeps IL-36 signaling in check. When that gene has a mutation, IL-36 signaling runs unchecked. This causes the intense skin inflammation seen in GPP.

Imsidolimab is a type of antibody drug called an IgG4 monoclonal antibody. It’s an engineered protein that attaches to the IL-36 receptor and stops IL-36 from binding to it. Think of it as putting a cover over a lock so the key can’t fit.

Without the signal getting through, the chain reaction that causes GPP flares can’t begin.

This approach is similar to spesolimab (Spevigo), the only GPP treatment approved so far. Spesolimab also blocks the IL-36 receptor, targeting the same signaling pathway. The two drugs differ in structure and how they bind. This may affect how each patient responds.

Having two drugs that target the same pathway gives doctors more options for patients who don’t respond to one.

What Did the Phase 3 Trials Show?

In the GEMINI-1 and GEMINI-2 Phase 3 trials, 53% of patients receiving a single IV dose of imsidolimab achieved GPPGA 0/1 (clear or almost clear skin) at week 4, compared to 13% on placebo. The drug kept working through about 2 years of monthly doses. The drug was well tolerated with no unexpected safety signals.

The trial design reflects the acute nature of GPP:

• Initial treatment: A single intravenous (IV) dose during a GPP flare
• Week 4 response: 53% achieved clear or almost clear skin (GPPGA 0/1) vs. 13% placebo
• Maintenance phase: Monthly doses to prevent new flares
• Long-term data: Efficacy maintained through approximately 2 years

The 53% vs. 13% difference is clinically meaningful for a condition where flares can be life-threatening. Clearing skin fast during a GPP flare isn’t just about looks. It lowers the body-wide inflammation that can harm organs, cause severe pain, and lead to intensive hospital care.

The long-term data matters just as much. GPP tends to flare repeatedly, and preventing those flares is a primary treatment goal. Two years of lasting response with monthly doses suggests imsidolimab could prevent flares, not just treat them.

What GPP Treatments Already Exist?

Spesolimab (Spevigo), approved in 2022, is the only FDA-approved drug made for GPP acute flares. Before spesolimab, doctors used off-label drugs like cyclosporine, acitretin, methotrexate, and biologics made for plaque psoriasis. If imsidolimab is approved, GPP patients would have two targeted options.

Currently, the treatment landscape for GPP is extremely limited:

• Spesolimab (Spevigo): The only FDA-approved GPP treatment, approved in 2022 for acute flares. Given as a single IV infusion. Has shown flare prevention in ongoing studies.
• Off-label treatments: Before spesolimab, doctors relied on drugs approved for other conditions, including cyclosporine, acitretin, methotrexate, and biologic therapies designed for plaque psoriasis. These drugs vary in how well they work for GPP and have limited proof.

If imsidolimab is approved, people with GPP would have two FDA-approved drugs that target this disease’s pathway. That’s a big step for a condition that had zero approved treatments as recently as 2021.

Why Does a Second GPP Treatment Matter?

A second approved GPP treatment matters because not every patient responds to the first option. More options means better treatment choices and easier insurance access. Competition in a drug class also tends to lower prices and boost patient support programs.

For rare diseases, each new approved drug is very important because:

1. Not everyone responds to the first drug. Some GPP patients don’t achieve adequate clearance with spesolimab. Imsidolimab targets the same pathway differently, which may work for those patients.
2. Insurance access improves with options. Insurers are more likely to cover a drug class when multiple options exist. This reduces prior authorization barriers.
3. Doctor familiarity grows. Each new approval brings attention to GPP. This helps more skin doctors spot and properly diagnose it.
4. Research investment follows. More approved drugs show drug makers that the GPP market is worth pursuing. This may attract more research funding.

What Should GPP Patients Do Now?

Talk to your dermatologist about current treatment options including spesolimab, ask about open clinical trials for imsidolimab on ClinicalTrials.gov, consider genetic testing for IL36RN mutations to guide future treatment choices, and connect with support organizations like the National Psoriasis Foundation.

If you’re living with GPP or have been diagnosed with it, here are steps to consider:

1. Talk to your dermatologist about current options. If you haven’t tried spesolimab, ask whether it’s appropriate for your situation.
2. Ask about clinical trials. Imsidolimab may still have open studies. Check ClinicalTrials.gov for enrolling trials.
3. Get genetic testing. If you haven’t been tested for IL36RN mutations, ask your doctor about it. Knowing your genetic makeup can help guide treatment choices as IL-36 drugs become more available.
4. Connect with rare disease communities. The National Psoriasis Foundation and the Global Pustular Psoriasis Advocacy Group both offer support.

The FDA’s review is expected to conclude by December 12, 2026. If approved, imsidolimab could be available to patients in early 2027.

Understanding GPP vs. Other Types of Psoriasis

For the broader psoriasis community, understanding how GPP fits into the spectrum of psoriasis types can help with awareness:

• Plaque psoriasis (80-90% of cases): Raised, scaly patches; chronic and manageable with many treatment options
• Guttate psoriasis: Small, drop-shaped spots; often triggered by streptococcal infection
• Inverse psoriasis: Smooth, red patches in skin folds
• Erythrodermic psoriasis: Widespread reddening and shedding; rare and serious
• Generalized pustular psoriasis: Pustular flares across large body areas; rare and potentially life-threatening

If you have plaque psoriasis, you’re unlikely to develop GPP. They’re related, but different immune pathways drive them. Still, knowing about GPP matters. Some people with plaque psoriasis have family members with GPP. Catching a flare early can be lifesaving.

Frequently Asked Questions

What is generalized pustular psoriasis?

GPP is a rare, severe form of psoriasis that causes sudden flares of pus-filled blisters across large areas of the body. Unlike plaque psoriasis, GPP can cause systemic symptoms like fever and may require hospitalization.

Is imsidolimab available now?

No. Imsidolimab is currently under FDA review with a decision expected by December 12, 2026. It’s not available outside of clinical trials at this time.

How is imsidolimab given?

Imsidolimab is given as an intravenous (IV) infusion. The initial dose is a single infusion during a GPP flare, followed by monthly maintenance infusions to prevent future flares.

What’s the difference between imsidolimab and spesolimab?

Both target the IL-36 pathway by blocking the IL-36 receptor. They differ in their molecular structure and binding characteristics, which may affect how individual patients respond to each drug.

Can imsidolimab treat plaque psoriasis?

Imsidolimab is being developed specifically for GPP. Plaque psoriasis is primarily driven by the IL-23 and IL-17 pathways rather than IL-36, so it’s not expected to be an effective plaque psoriasis treatment.

Is GPP genetic?

Many cases of GPP are linked to mutations in the IL36RN gene, though not all patients carry this mutation. Having the mutation increases your risk, but other factors also contribute to whether someone develops GPP.

Sources

1. Vanda Pharmaceuticals. “Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis.” PRNewswire. 2025. https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html
2. HCPLive. “FDA Accepts BLA for Imsidolimab for Generalized Pustular Psoriasis Treatment.” HCPLive. 2026. https://www.hcplive.com/view/fda-accepts-bla-imsidolimab-generalized-pustular-psoriasis-treatment
3. Dermatology Times. “Vanda Files BLA for Imsidolimab in Generalized Pustular Psoriasis.” Dermatology Times. 2025. https://www.dermatologytimes.com/view/vanda-files-bla-for-imsidolimab-in-generalized-pustular-psoriasis
4. BioSpace. “Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab.” BioSpace. 2026. https://www.biospace.com/press-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis